Home / Longevity / Vilon
VlHuman trials

Vilon protocol

Vilon is a 2-amino-acid peptide (Lys-Glu) from a Russian research group. It has been used in small Russian clinical studies, mostly as an add-on to normal treatment. It is not approved as a medicine in the US or EU.

Russia gave permission for clinical trials in 2002Not approved as a drug in the US or EU
ProtocolMixingResultsSide effectsHow it worksSources

The protocol at a glance

The studies used short daily courses of 5 to 10 days. The one dose I could read clearly is 1 mg a day for 10 days, repeated 3 times a month apart.

StudyAmount and length
Colorectal cancer, 57 patients1 mg a day for 10 days, repeated 3 times, 1 month apart
Surgical patients, 63 (double-blind)Into the muscle once a day for 7 or 10 days (amount unreadable in my copy)
Gum disease in older adults, 250+Under the gum lining daily for 5 to 10 days (amount unreadable in my copy)

All three come from the developing group's own 2014 review (Khavinson, Kuznik, Ryzhak). Only the 63-patient trial is called double-blind and randomized. The unit symbol was lost in the PDF text I read, so I left those two amounts out.

Community reports

Community notes report 200 mcg to 1 mg a day for 10 to 20 days. These are user reports, not trial data.

What people say they do, collected from community discussions. Not tested in a trial; shown so you can compare it with the evidence above.

Mixing

No mixing table here: this one is used as a capsule, nasal spray or skin product, or has no human amount to calculate from. The general mixing calculator works for any vial.

What the trials found

Results are as reported in the developers' review. Most studies were add-on designs without blinding mentioned:

85.8% vs 37%Two-year survival with Vilon vs control in colorectal cancer (57 patients)
1.5 days soonerPoisoning symptoms cleared sooner in erysipelas patients on Vilon vs control
150Type 1 diabetes patients; many needed less insulin, about 9 units on average
63Surgical patients in the double-blind trial; the review says tissue repair was faster

Khavinson VKh, Kuznik BI, Ryzhak GA. Adv Gerontol 2014;4(4):346-361 (clinical-trials review by the developers). No independent replication found.

Side effects

  • The review reports fewer complications and fewer chemotherapy side effects in the cancer group, and gives no side-effect table.
  • No independent safety data found.

How it works

Developer-reported

The developers say Vilon speeds tissue repair and boosts immune cells. These claims come from their own review.

Gene activity (lab)

In human stem-cell cultures, the KE peptide raised SIRT1 and lowered PARP1 and PARP2.

Sources

  • Khavinson VKh, Kuznik BI, Ryzhak GA. Peptide bioregulators: results of clinical trials. Adv Gerontol 2014;4(4):346-361
  • KE peptide regulates SIRT1, PARP1, PARP2 in stem-cell ageing. Adv Gerontol 2023, PMID 37782636
  • ClinicalTrials.gov search by intervention name, run 5 Nov 2026: 0 results